Metabolism Disorder TRIZ Cases

Stilbene compounds improve poultry health by increasing villi surface area while avoiding antimicrobial resistance.

Small molecule compounds of formula I enable oral administration to inhibit PCSK9 and reduce LDL-C, replacing inconvenient antibody injections.

Amphiphilic compounds prevent amylin fibril formation at neutral pH, enabling stable co-administration with insulin.

4-cresol compounds improve glucose homeostasis without hypoglycemia risks.

A basal insulin delivery system selects tailored infusion patterns based on patient characteristics to optimize glycemic control.

A pet food formulation with a specific protein to fat ratio reduces post-prandial 3-methylhistidine levels, preventing skeletal muscle breakdown and sarcopenia.

Gold kiwifruit powder prebiotics merge with Bacillus coagulans probiotics to address constipation symptoms and cholesterol levels.

Amino acid substitutions and fatty acid acylation create incretin analogs with balanced GIP, GLP-1, and glucagon receptor activity.

Pegylated CRHR2 peptide agonists improve cardiac output while avoiding proarrhythmic potential of traditional inotropes.

Engineered GDF15 polypeptides use pegylation and albumin fusion to improve solubility, reducing adverse effects from current treatments.

Microwave treatment reduces moisture before supercritical extraction prevents lipid oxidation, lowering production costs.

Chitosan-coated activated carbon increases gas and cholesterol adsorption, treating hypercholesterolemia without side effects.

Glucose control indicators assess chronic dysglycemia in infants using total whole blood protein fractions.

Anti-ActRIIB antibodies increase brown adipose tissue without elevating red blood cell levels, avoiding hematological changes.

A Mormodica charantia polypeptide regulates multiple genes and targets inflammatory pathways.

Polymeric IgA with secretory component resists gastric degradation to inhibit retrotranscytosis of pathogenic peptides.

Transgenic rice biosynthesizes resveratrol via inserted synthase genes, reducing blood glucose and body fat without extraction.

An antibody recognizes amino acids at positions 629 to 633 of the human transferrin receptor.

Composite sweetener systems mask off-tastes and balance flavor to replace sugar in low-calorie condiments.

A porous scaffold enables vascularized collagen matrix formation to prevent immune rejection and ischemia during cellular therapy.

A recombinant E. coli cell line uses a thermoswitch upstream leader sequence to regulate essential gene expression.

A marine oil supplement formulation adjusts fatty acid proportions to achieve a balanced lipid profile.

Hafnia alvei probiotics reduce hyperphagia, fat mass, and glucose levels without Orlistat side effects.

Modified glucagon derivatives enhance solubility and chemical stability through targeted amino acid substitutions.

Aprotic polar solvents dissolve glucagon to prevent hydrolysis and degradation, enabling stable sustained release depot formulations.

Merges naltrexone and bupropion to resolve the trade-off between depression treatment effectiveness and patient weight gain.

Trigonelline delays atrophy onset and retains muscle mass by promoting myogenic differentiation, preventing sarcopenia.

A double-receptor agonist protein activates GLP-1 and GIP receptors to enhance blood glucose control.

Homing endonuclease variants cleave the PCSK9 gene to lower LDL-C levels, addressing residual cardiovascular risk from statin intolerance.

Formula I tetrazole derivatives inhibit BCKDK to restore BCAA catabolism in diabetes and NASH.

Cimicifuga racemosa extract activates AMPK to resolve insufficient blood glucose lowering in type 2 diabetes.

Intracerebroventricular injection bypasses the blood-brain barrier to treat Hunter syndrome.

Deuterium labeling tracks glucose derivatives to estimate fractional gluconeogenesis for metabolic state assessment.

Hemopressin derivatives act as CB1 receptor inverse agonists to oxidize blood plasma free fatty acids.

Segmented peptide structures resist DPP-IV degradation to prolong circulation time for improved glucose control.

UGT2B inhibitors increase morphine-like analgesic bioavailability through targeted enzyme modulation.

Combining long-acting and rapid-acting insulin enables flexible dosing at the largest daily meal.

Anion exchange chromatography captures recombinant lysosomal proteins, increasing mannose-6-phosphate residues to improve tissue targeting efficiency.

Lipid nanoparticles deliver modified mRNA encoding human ornithine transcarbamylase to hepatocytes.

A topical plant extract weight reduction system applies natural products to the epidermal layer to dissolve adipose tissue.

Hydrophobic side chains on insulin B chains enable physiological pH solubility, reducing immunogenicity and local irritation.

5-D-fructose dehydrogenase converts fructose into 5-keto-D-fructose to reduce bioavailability.

Tph1 inhibitors reduce peripheral serotonin to enhance brown adipose tissue activity and energy expenditure.

Pre-conditioning dendritic cells with dexamethasone and vitamin D2 prevents phenotypic switching in inflammatory environments.

Segmented granulation with lactose coating prevents other active ingredients from hindering insulin sensitizer release rates.

PEGylated fusion proteins extend half-life and reduce immunogenicity for stable glycemic control.

A dietary supplement combining short chain fatty acids with epigallocatechin gallate to induce ketosis and modulate Sirtuin protein expression.